Childhood Cancer Survivor Study (CCSS)(Limited Competition U24)

The summary for the Childhood Cancer Survivor Study (CCSS)(Limited Competition U24) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Childhood Cancer Survivor Study (CCSS)(Limited Competition U24)
	CFDA Number:	93.395
	CFDA Description:	Cancer Treatment Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Education Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-CA-11-501
	Document Type:	Grants Notice
	Funding Instrument Type:	Cooperative Agreement
	Posted Date:	Feb 17, 2011
	Creation Date:	Feb 17, 2011
	Original Closing Date for Applications:	Apr 21, 2011
	Current Closing Date for Applications:	Apr 21, 2011
	Archive Date:	May 22, 2011
	Expected Number of Awards:	1
	Estimated Total Program Funding:	4,380,000
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Information not provided
Grant Description: The purpose of this Funding Opportunity Announcement (FOA) is to continue support for Childhood Cancer Survivor Study (CCSS) as a resource enabling broad studies on the long-term effects of cancer and its associated therapies on survivors of pediatric cancers. CCSS (originally funded as an investigator initiated program) serves the overall goal to quantify and better understand the effects of pediatric cancer and its treatment on later health of cancer survivors, including behavioral and sociodemographic outcomes. For these goals, CCSS has been designed as a comprehensive multicenter effort to comprehensively manage large cohorts of survivors of childhood cancer. The original cohort of study participants included 14,370 pediatric cancer survivors diagnosed between 1970 and 1986 as well as 3,737 siblings. Enrollment of a second cohort of survivors consisting of a similar number of subjects diagnosed between 1987 and 1999 is expected to be completed by the end of the current award period. The current CCSS structure includes 27 institutions, mostly in the U.S. but also in Canada.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/rfa-ca-11-501.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Core Clinical Centers (U10); • Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Data Coordinating Center (U10); • Paul Calabresi Career Development Award for Clinical Oncology (K12); • Cancer Immunotherapy Trials Network (U01); • Developmental Projects in Complementary Approaches to Cancer Care and Treatment (R03); • Breast and Prostate Cancer Data Quality and Patterns of Care Study; • CONSORTIUM THERAPEUTIC STUDIES OF PRIMARY CENTRAL NERVOUS SYSTEM MALIGNANCIES IN ADULTS; • NATIONAL COOPERATIVE DRUG DISCOVERY GROUPS FOR CANCER; • Pediatric Phase 1/Pilot Consortium (U01); • Advanced Technology Radiation Therapy Clinical Trials Support (ATC) (Limited Competition U24)